CCKBR and major depressive disorder: Our laboratories have refined a rapid eukaryotic ribosome display method to develop panels to target P2X4 [2] and cholecystokinin B (CCK-B) receptors [5] to reduce hypersensitivity, anxiety, and depression in our chronic pain models.